LIMINATUS PHARMA INC (LIMN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.71+0.27%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · LIMN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of —
LIMN — legal / regulatory event — Notice of Delisting or Failure to
Dated 2026-08-18
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on November 19, 2025, Liminatus Pharma, Inc., a Delaware corporation (the “Company”), received notices from The Nasdaq Stock Market (“Nasdaq”) indicating that the Company was no longer in compliance with the following continued listing requirements of The Nasdaq Global Market: (i) Listing Rule 5450(b)(2)(A), which requires a listed company to maintain a minimum Market V…
Why it matters: Earnings results will show the company's financial health and progress on goals.
Watch forQ3 earnings show revenue growth or positive cash flow.
Also watch forQ3 earnings report shows more losses or falling revenue.
Why it matters: The merger could enhance growth and market position. Future M&A plans are crucial for expansion.
Supportive ifThere may be more M&A activities or partnerships after the InnocsAI merger.
Worry ifNo new M&A announcements or signs of stagnation in growth strategy.
Why it matters: M&A can drive growth and strategic positioning. Investors will look for new deals.
Supportive ifThe company announces a new deal or partnership.
Worry ifNo new M&A activity is reported in the coming quarters.
Why it matters: Good use of capital helps the company grow. Investors will look for progress.
Supportive ifThe company announces a new way to raise money or invest.
Worry ifThe company says there is no progress in capital use.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$415 on $10,000 · ±4.2% | How much price usually moves either way. |
| Bad day | $1,478 loss on $10,000 · 14.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,727 loss on $10,000 · 97.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The company is deciding how to use its money. Changes may affect operations funding.
Watch forThere is a new plan for raising capital or investing that helps with funding.
Also watch forThere is a freeze on capital allocation or more share dilution.
Why it matters: The reverse stock split is aimed at regaining compliance with Nasdaq listing rules.
Supportive ifThe reverse stock split is completed successfully on August 20, 2026.
Worry ifThe reverse stock split is delayed or fails to occur.
Why it matters: The company faces delisting risks. Staying compliant is crucial for its future.
Worry ifThe company said it has met Nasdaq's $50M market value rule.
Less concerning ifThere is another notice of delisting or not meeting Nasdaq standards.
Why it matters: The company has received multiple notices about not meeting Nasdaq listing rules. This affects its stock status.
Worry ifLiminatus Pharma says it is back in line with Nasdaq listing rules.
Less concerning ifAnother notice says it may be delisted or still not follow Nasdaq rules.
Why it matters: The reverse stock split aims to improve share price and compliance with Nasdaq.
Supportive ifShare price stabilizes or increases following the reverse stock split.
Worry ifShare price drops a lot after the reverse stock split.
Why it matters: The company got money from warrant exercises. How it uses this money matters.
Watch forA clear plan detailing the use of the $1.9 million raised from warrant exercises.
Also watch forNo clear communication on how the funds will be allocated or spent.
Why it matters: If stockholders say yes to the new warrants, Liminatus could get money.
Supportive ifStockholders approve the new warrants. This allows them to be used.
Worry ifStockholders do not approve. This stops the new warrants from being used.
Why it matters: Updates on Nasdaq rules will show if Liminatus can stay listed.
Worry ifThe company gets a notice that it meets Nasdaq listing rules.
Less concerning ifNasdaq sends more notices of non-compliance. This shows there are still problems.
Why it matters: The reverse stock split could impact share price and investor perception of stability.
Watch forThe reverse stock split is done. Shares trade based on the new split.
Also watch forProblems happen during the reverse stock split. This causes delays or issues.